Health
Experimental Drug Wards Off Both Lung and Breast Cancer Progression in Trials
- Portion of study results released early at medical conference
- Daiichi shares slump amid incomplete data on Dato-DXd
This article is for subscribers only.
A new cancer medicine developed by AstraZeneca Plc and Daiichi Sankyo Co. seemed to fall short of investors’ expectations in partial results released early after a data leak at a medical conference.
The experimental drug was designed to stave off worsening of both lung and breast cancers for patients with few other options in a pair of highly anticipated studies. Astra shares dropped as much as 4.5% in London trading. Daiichi fell as 4.6% in Tokyo.